Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the price of Ordinary share ADRs at $29.58 per ADR, which was the price used for dividend re-investment.
Material Changes
The document reports an increase in share interests for specific individuals following the re-investment of dividends paid on April 9, 2009. No material changes to the company's overall financial position or operations are detailed in this filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of director transactions.
Important Facts for Investors
- Transaction Type: Increase in Ordinary share ADR interests via dividend re-investment.
- Participants: Mr. E J Gray (20.36 ADRs) and Mr. D J Phelan (617.29 ADRs).
- Transaction Price: $29.58 per ADR.
- Dividend Date: April 9, 2009.
- Reporting Date: May 11, 2009.